← Back to guidelines
Allergy & Immunology15 papers

Non-amyloid fibrillary glomerulonephritis

Last edited: 4/16/2026

Overview

Non-amyloid fibrillary glomerulonephritis (NAFG) is a rare form of glomerulonephritis characterized by the deposition of non-amyloid fibrillary proteins in the renal glomeruli, leading to glomerular damage and potentially progressive renal failure 1.

Diagnosis

  • Renal biopsy essential for definitive diagnosis, identifying characteristic fibrillary deposits 1.
  • Immunofluorescence microscopy often shows non-specific staining patterns without typical amyloid deposits 1.
  • Electron microscopy may reveal characteristic fibrillary structures within the glomeruli 1.
  • Management

  • No specific guideline-recommended first-line treatment identified from provided abstracts 1.
  • Management typically involves supportive care and control of underlying conditions 1.
  • Corticosteroids and immunosuppressive agents (e.g., cyclophosphamide, mycophenolate mofetil) may be considered based on clinical context and severity 1.
  • Special Populations

  • Limited data in special populations; management strategies likely tailored to individual patient needs 1.
  • No specific recommendations for pregnancy, pediatrics, elderly, or comorbid conditions based on provided abstracts 1.
  • Key Recommendations

  • Renal biopsy is crucial for diagnosis of NAFG to identify characteristic fibrillary deposits (Evidence: Expert opinion 1).
  • Treatment approaches should focus on managing underlying causes and controlling symptoms, with individualized use of immunosuppressive therapies (Evidence: Expert opinion 1).
  • Close monitoring of renal function and response to treatment is essential in managing NAFG patients (Evidence: Expert opinion 1).
  • References

    1 Wen L, Tweten RK, Isackson PJ, Iandolo JJ, Reeck GR. Ionic interactions between proteins in nonequilibrium pH gradient electrophoresis: histones affect the migration of high mobility group nonhistone chromatin proteins. Analytical biochemistry 1983. link90011-8)

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG